The International Consensus TIR (IC-TIR) does not have recommendations on the frequency of CGM use in clinical practice. In South Asia, where the diabetes device market is non-reimbursable, people with diabetes need to spend out of their pocket and hence cannot use CGM year long. But CGM provide numerous advantages to people with diabetes for better glycemic control.

Considering the limitations for the continuous use of CGM for a majority of patients with T2D in South Asia and the advantages of CGM use, a recent article published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews from Jothydev’s Diabetes Research Centre recommends a minimum frequency for the assessment of TIR in T2D. For those patients achieving a desirable TIR with minimal time below range, the frequency of repeating the test is kept minimal and vice versa. The expert panel also suggests that based on the clinical judgment the treating physician can decide on the frequency of repeating the CGM. In subjects more vulnerable to hypoglycemia, the CGM should be repeated more frequently.